Stock Scorecard
Stock Summary for AbCellera Biologics Inc (ABCL) - $4.34 as of 8/22/2025 7:40:13 PM EST
Total Score
8 out of 30
Safety Score
31 out of 100
Currently on the following lists
None
Tim's Recommendation
Avoid
Growth List Algorithm Criteria for ABCL
Positive Quarterly and Annual earnings growth | |
P/E ratio less than Industry P/E Ratio | |
P/E ratio less than Sector P/E Ratio | |
P/E ratio that is half the Annual earnings growth rate (or less) | |
Positive net cash position the past year and most recent quarter | |
Equity to debt ratio greater than 0.75 for past year and most recent quarter | |
Positive net income past year and 12 trailing months | |
Free cash flow ratio greater than 0 and less than 10 |
Small Cap List Algorithm Criteria for ABCL
Revenue growing by at least 20% average per year over the last 5 years | |
Market Capitalization under 2 billion | |
Price to Sales (P/S) ratio 12 trailing months less than Industry P/S ratio twelve trailing months | |
Price to Sales (P/S) ratio 12 trailing months less than Sector P/S ratio twelve trailing months | |
Net Income past year > Net Income prior year OR Net Income 12 trailing months > Net Income prior year OR Net Income 12 trailing months > Net Income past year |
Dividend List Algorithm Criteria for ABCL
Declared an ex-dividend date | |
Forward annual dividend rate greater than 2 | |
Positive net cash position the past year and most recent quarter | |
Equity to debt ratio greater than 0.75 for past year and most recent quarter | |
Current ratio most recent quarter greater than 2 | |
Cash Flow per Share greater than Trailing Dividend Rate |
Bonus Criteria for ABCL
P/E ratio less than five-year Average P/E ratio | |
Last Price to 52 Week Low Ratio Less Than 1 | |
Total Cash Per Share > Last Day Price | |
P/S Ratio < 1 | |
P/B Ratio < 1 |
Safety Rating Criteria for ABCL (31 out of 100)
Stock Price Rating (Max of 10) | 3 |
Historical Stock Price Rating (Max of 10) | 5 |
Stock Price Trend (Max of 10) | 1 |
Book Value (Max of 10) | 3 |
Book Value to Price (Max of 10) | 1 |
Analyst Buy Ratings (Max of 5) | 5 |
Analyst Strong Buy Ratings (Max of 5) | 3 |
Dividend Yield Percentage (Max of 10) | 0 |
Operating Margin (Max of 10) | 0 |
Trading Volume (Max of 10) | 10 |
Price to Earnings (Max of 10) | 0 |
Geopolitical Risk Adjustment (Always 0 for USA or a Negative Number for Non-USA) | 0 |
Latest News for for ABCL
Financial Details for ABCL
Company Overview |
|
---|---|
Ticker | ABCL |
Company Name | AbCellera Biologics Inc |
Country | USA |
Description | AbCellera Biologics Inc. develops an antibody discovery platform. The company is headquartered in Vancouver, Canada. |
Sector Name | LIFE SCIENCES |
Industry Name | PHARMACEUTICAL PREPARATIONS |
Most Recent Quarter | 6/30/2025 |
Next Earnings Date | 11/11/2025 |
Stock Price History |
|
Last Day Price | 4.34 |
Price 4 Years Ago | 14.30 |
Last Day Price Updated | 8/22/2025 7:40:13 PM EST |
Last Day Volume | 4,111,858 |
Average Daily Volume | 6,434,069 |
52-Week High | 5.82 |
52-Week Low | 1.89 |
Last Price to 52 Week Low | 129.63% |
Valuation Measures |
|
Trailing PE | N/A |
Industry PE | 40.56 |
Sector PE | 58.53 |
5-Year Average PE | 4.35 |
Free Cash Flow Ratio | 14.00 |
Industry Free Cash Flow Ratio | 15.42 |
Sector Free Cash Flow Ratio | 30.30 |
Current Ratio Most Recent Quarter | 11.07 |
Total Cash Per Share | 0.31 |
Book Value Per Share Most Recent Quarter | 3.40 |
Price to Book Ratio | 1.28 |
Industry Price to Book Ratio | 29.05 |
Sector Price to Book Ratio | 26.66 |
Price to Sales Ratio Twelve Trailing Months | 39.09 |
Industry Price to Sales Ratio Twelve Trailing Months | 25.49 |
Sector Price to Sales Ratio Twelve Trailing Months | 13.25 |
Analyst Buy Ratings | 7 |
Analyst Strong Buy Ratings | 1 |
Share Statistics |
|
Total Shares Outstanding | 298,833,000 |
Market Capitalization | 1,296,935,220 |
Institutional Ownership | 38.52% |
Dividends |
|
Ex-Dividend Date | N/A |
Previous Dividend Amount | 0.0000 |
Current Dividend Amount | 0.0000 |
Total Years Dividend Increasing | N/A |
Trailing Annual Dividend Rate | 0.00 |
Trailing Annual Dividend Yield | 0.00% |
Forward Annual Dividend Rate | 0.00 |
Forward Annual Dividend Yield | 0.00% |
5-Year Dividend Payments Count | 0 |
3-Year Average Dividend Yield | 0.00% |
5-Year Average Dividend Yield | 0.00% |
1-Year Dividend Growth Rate Percentage | 0.00% |
3-Year Dividend Growth Rate Percentage | 0.00% |
5-Year Dividend Growth Rate Percentage | 0.00% |
All-Time Dividend Growth Rate Percentage | 0.00% |
Dividend Payout Ratio | N/A |
Income Statement |
|
Quarterly Earnings Growth YOY | 45.90% |
Annual Earnings Growth | -11.24% |
Reported EPS 12 Trailing Months | -0.56 |
Reported EPS Past Year | -0.27 |
Reported EPS Prior Year | -0.56 |
Net Income Twelve Trailing Months | -165,665,000 |
Net Income Past Year | -162,857,000 |
Net Income Prior Year | -146,398,000 |
Quarterly Revenue Growth YOY | 133.30% |
5-Year Revenue Growth | 19.95% |
Operating Margin Twelve Trailing Months | -290.20% |
Balance Sheet |
|
Total Cash Most Recent Quarter | 92,437,000 |
Total Cash Past Year | 156,325,000 |
Total Cash Prior Year | 133,320,000 |
Net Cash Position Most Recent Quarter | 92,437,000 |
Net Cash Position Past Year | 154,127,000 |
Long Term Debt Past Year | 2,198,000 |
Long Term Debt Prior Year | 2,198,000 |
Total Debt Most Recent Quarter | 0 |
Equity to Debt Ratio Past Year | 1.00 |
Equity to Debt Ratio Most Recent Quarter | 1.00 |
Total Stockholder Equity Past Year | 1,056,084,000 |
Total Stockholder Equity Prior Year | 1,152,318,000 |
Total Stockholder Equity Most Recent Quarter | 1,007,076,000 |
Free Cash Flow |
|
Free Cash Flow Twelve Trailing Months | -138,987,000 |
Free Cash Flow Per Share Twelve Trailing Months | -0.47 |
Free Cash Flow Past Year | -186,952,000 |
Free Cash Flow Prior Year | -121,384,000 |
Options |
|
Put/Call Ratio | 0.26 |
Has Options | Options Chain |
Liquidity Rating | |
Technical Analysis |
|
Yahoo Finance Chart | Yahoo Finance Chart |
MACD | 0.06 |
MACD Signal | 0.12 |
20-Day Bollinger Lower Band | 1.25 |
20-Day Bollinger Middle Band | 3.27 |
20-Day Bollinger Upper Band | 5.28 |
Beta | 0.65 |
RSI | 45.96 |
50-Day SMA | 2.96 |
150-Day SMA | 5.22 |
200-Day SMA | 6.60 |
System |
|
Modified | 8/22/2025 4:18:30 PM EST |